Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25565746 | 0.95 | PAOX (0.36) | PAOXALDH1A1NPC1RAB9AAPAF1 | |
| SCHEMBL23384019 | 0.93 | PAOX (0.39) | PAOXALDH1A1NPC1RAB9AAPAF1 | |
| SCHEMBL25569452 | 0.91 | PAOX (0.38) | PAOXALDH1A1NPC1RAB9AAPAF1 | |
| SCHEMBL19546118 | 0.91 | PAOX (0.34) | PAOXALDH1A1NPC1RAB9AAPAF1 | |
| SCHEMBL25566310 | 0.88 | PAOX (0.35) | PAOXALDH1A1SIGMAR1CACNA2D1HRH3 | |
| SCHEMBL21954706 | 0.87 | HRH4 (0.33) | HRH3 | |
| SCHEMBL10617953 | 0.87 | CYP1A2 (0.41) | PAOXALDH1A1NPC1RAB9ASIGMAR1 | |
| SCHEMBL25075491 | 0.87 | EPHX1 (0.33) | PAOXALDH1A1HRH3 | |
| SCHEMBL12085574 | 0.86 | PAOX (0.40) | PAOXALDH1A1NPC1RAB9AAPAF1 | |
| SCHEMBL17766692 | 0.85 | HRH4 (0.32) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107698755-B | Cationic polymer and preparation method and application thereof | 四川大学 | 2021-03-30 | — | — | CN | claimed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023122759-A2 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | AKAGERA MEDICINES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | UNIVERSITY OF KANSAS | 2022-04-28 | — | — | US | disclosed |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| CN-107698755-B | Cationic polymer and preparation method and application thereof | 四川大学 | 2021-03-30 | — | — | CN | disclosed |
| WO-2019185025-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | 正大天晴药业集团股份有限公司 | 2019-10-03 | — | — | WO | disclosed |
| EP-3002287-B1 | Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors | NAT DEFENSE MEDICAL CENTER (TW) | 2018-01-31 | — | — | EP | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | UNIVERSITY OF KANSAS | 2017-11-23 | — | — | US | disclosed |
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919623-B2 | Naphthyridine derivatives having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498349-B2 | Biaryl compounds having anti-infective activity | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221046-A1 | Macrolides With Anti-Inflammatory Activity | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| US-7301037-B2 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221046-A1 | Macrolides With Anti-Inflammatory Activity | IL5, IL2, IL1A | PAOX 3727/4885ALDH1A1 3686/4885NPC1 815/4885 |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | PAOX 3626/4885ALDH1A1 4719/4885NPC1 1997/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | PAOX 1325/4885ALDH1A1 3948/4885NPC1 1015/4885 |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | PAOX 2058/4885ALDH1A1 250/4885NPC1 3662/4885 |
| US-20170334842-A1 | INHIBITORS OF THE MITF MOLECULAR PATHWAY | MITF, TFEB, TYR | PAOX 1113/4885ALDH1A1 2444/4885NPC1 2867/4885 |
| US-20090227621-A1 | Naphthyridine derivatives having inhibitory activity against hiv integrase | PNP, CDKL1, ASNS | PAOX 4112/4885ALDH1A1 2740/4885NPC1 1366/4885 |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | PAOX 1194/4885ALDH1A1 3295/4885NPC1 1753/4885 |
| US-20220128562-A1 | BIOMARKERS PREDICTIVE OF CANCER CELL RESPONSE TO ML329 OR A DERIVATIVE THEREOF | NQO1, KEAP1, NFE2L2 | PAOX 2540/4885ALDH1A1 287/4885NPC1 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.